The importance of the Life Sciences sector for the economy of the canton of Fribourg
A study by BAK Economics commissioned by GRIP-pharma and FDA
Life Sciences is a major sector of Fribourg's economy, generating a value added of more than CHF 1.5 billion in 2023 and employing 3,300 full-time equivalents (FTEs). Numerous companies in other sectors of the economy also benefit from the activities of the Life Sciences sector. A total value added of CHF 1.96 billion, representing 10% of Fribourg's economy, is generated directly and indirectly by Life Sciences activities. These are the main findings of a study by BAK Economics on the importance of the Life Sciences sector for the economy of the canton of Fribourg. The study is a joint project between the GRIP-pharma association, the Fribourg Development Agency and Life Sciences companies operating in the canton of Fribourg (CSL Vifor, Grifols, OM Pharma, UCB and Verfora).